"name","instanceType","uuid:ID","id","rationale","description","label"
"Study Design 1","StudyDesign","7984ed19-ba4d-4c09-b9ef-558f90d92830","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study",""
